Showing results (141-150 of 545) with videos related to
Sort By:
Pageof 55
Cancers|March 13, 2025
Cyclin-Dependent Kinase Inhibition in Prostate Cancer: Past, Present, and FutureMatthew Siskin, Minas P Economides, David R WiseAntimicrobial Agents and Chemotherapy|June 1, 1990
Mechanism of action of lomefloxacinL J Piddock, M C Hall, R WiseThe Journal of Antimicrobial Chemotherapy|June 25, 1999
Study to assess the reliability of a disc diffusion method for determining the sensitivity of gram-positive pathogens to dalfopristin/quinupristinJ M Andrews, J P Ashby, R WiseThe Journal of Antimicrobial Chemotherapy|November 1, 1990
In-vitro activity of cefodizime against respiratory pathogensR Wise, J M Andrews, J P AshbyAntimicrobial Agents and Chemotherapy|November 1, 1992
In vitro activity of RU 29246, the active compound of the cephalosporin prodrug ester HR 916G Riess, J Andrews, D Thornber, et al.The Journal of Antimicrobial Chemotherapy|February 1, 1985
The in-vitro activity of Ro 17-2301, a new monobactam, compared with other antimicrobial agentsR Wise, J M Andrews, L J PiddockAntimicrobial Agents and Chemotherapy|June 1, 1986
In vitro activity of Ro 15-8074 and Ro 19-5247, two orally administered cephalosporin metabolitesR Wise, J M Andrews, L J PiddockAntimicrobial Agents and Chemotherapy|August 4, 1998
Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniaeN P Brenwald, M J Gill, R WiseAntimicrobial Agents and Chemotherapy|September 1, 1979
LY127935, a novel oxa-beta-lactam: an in vitro comparison with other beta-lactam antibioticsR Wise, J M Andrews, K A BedfordJournal of Clinical Pathology|November 1, 1979
Interference of cefoxitin in the creatinine estimation and its clinical relevanceS R Durham, A H Bignell, R WisePageof 55